Back to results
US 9,000,154 B2Granted
Rho kinase inhibitors
AssigneeBoehringer Ingelheim International GmbH
InventorsThomas Martin Kirrane, Daniel Richard Marshall, Robert Sibley, Roger John Snow, Fariba Soleymanzadeh, Ronald John Sorcek
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Claims11
A compound of the formula I
- wherein:
- X is selected from the group Xa consisting of
- A is C or N;
- Y is O or S;
- R1 is selected from the group R1a consisting of
- R2 and R3 are independently selected from H, —CH3, —OCH3, —F, —Cl, —C(O)NH2, and —CN, provided that R2 and R3 are not both H;
- R4 is H or —CH3;
- R5 is C1-6alkyl;
- R6 is selected from
- a heterocyclyl group selected from piperidinyl, piperazinyl, morpholinyl, 2,3-dihydroindolyl and pyrrolidinyl, and
- —N(R7)(R8),
- wherein the heterocyclyl group may be substituted with one to three groups selected from halogen, oxo, C1-3alkyl and C3-6cycloalkyl;
- R7 and R8 are independently selected from H, C1-3alkyl, C3-6cycloalkyl and CO2C1-4-alkyl, wherein the C1-3alkyl and C3-6cycloalkyl are optionally substituted with —OCH3, —CF3, —CHF2 or —CN;
- and
- n is 1 or 2;
- or a salt thereof.
13 more elements
A compound selected from the group consisting of
- and the pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.